[Form 3] Iovance Biotherapeutics, Inc. Initial Statement of Beneficial Ownership
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Rosinack Matthew W.
Role
SVP, Finance (Int. PFO & PAO)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 75,000 shares (Direct);
Restricted Stock Units — 11,721 shares (Direct);
Common Stock — 89,129 shares (Direct)
Footnotes (1)
- Includes 9,089 shares of Iovance Biotherapeutics, Inc.'s (the "Issuer") common stock purchased under the Issuer's 2020 Employee Stock Purchase Plan. The stock option was granted on September 27, 2021. The shares underlying this option are fully vested. The restricted stock units ("RSUs") were granted on March 2, 2023. One-third of the RSUs vested on March 2, 2024. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter. The RSUs were granted on March 1, 2024. One-third of the RSUs vested on March 1, 2025. The remaining RSUs will vest or have vested in eight equal quarterly installments thereafter. The RSUs were granted on March 5, 2025. One-third of the RSUs will vest on March 5, 2026. The remaining RSUs will vest in eight equal quarterly installments thereafter. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
